Lateef WM, Hakeem ZA, Gani AA, Shadab NW, Nayeem Ul-Hassan, Farooq AG and Nasir-ud-In W
Peginterferon-alfa 2a or alfa 2b plus ribavirin is the treatment of choice in chronic hepatitis C. Severe adverse effects may compromise efficacy of this regiment. There are few reports of warm autoimmune hemolytic anemia following interferon-alfa or peginterferon-alfa2b plus ribavirin treatment. This present report discusses autoimmune hemolytic anemia which developed during peginterferon alfa-2a/ribavirin treatment and caused dose cessation. The anemia was improved with discontinuation of peginterferon-alfa 2a/ribavirin and adminstration of erythropoietin stimulating agent.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 